Meeting
2013 ASCO Annual Meeting
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
Authors
Kathryn Maree Field
Royal Melbourne Hospital, Parkville, Australia
Kathryn Maree Field , John Simes , Helen Wheeler , Elizabeth J. Hovey , Anna K. Nowak , Lawrence Cher , Chris Brown , Ann Livingstone , Kate Sawkins , Mark Rosenthal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
ACTRN12610000915055
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2017)
DOI
10.1200/jco.2013.31.15_suppl.2017
Abstract #
2017
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2019 ASCO Annual Meeting
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
First Author: Bart Neyns
Poster
2016 ASCO Annual Meeting
Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
First Author: Johnny Duerinck
Poster
2015 ASCO Annual Meeting
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
First Author: Vinay K. Puduvalli